Spanish biopharmaceutical company PharmaMar has selected Medidata Solutions' Medidata Clinical Cloud platform to accelerate clinical trials for marine-based oncology drugs.
A member of the Zeltia Group and a developer of antitumor drugs of marine origin, PharmaMar will use Medidata Clinical Cloud platform to streamline its clinical trial processes.
PharmaMar earlier deployed Medidata Rave for use in all its forthcoming trials in addition to Safety Gateway and Medidata Coder technologies for capturing and coding the safety data.
PharmaMar clinical development director Dr. Arturo Soto said, "Our sites in Europe and the U.S. recommended Medidata for its ease of use. In implementing the Medidata Clinical Cloud we found that we had earlier access to reliable data to help us make decisions for optimal patient safety and patient experience."
The company is leveraging Medidata's knowledge transfer program to take technology management in-house.
Medidata president Glen de Vries said, "We commend PharmaMar for their innovative research in identifying new molecules through its marine-based research program for treatment of cancer and other diseases."
